AstraZeneca's Tagrisso gained European Commission approval for advanced non-small cell lung cancer, showing significant efficacy. Consequently, AstraZeneca's shares rose by 1.62% at market close.
The FDA revoked the emergency use authorization for AstraZeneca's Evusheld due to its expired shelf life and lack of patient administration approval for over a year.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.